Drug Profile
CCX 832
Alternative Names: CCX-832Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator ChemoCentryx
- Developer ChemoCentryx; GSK
- Class Anti-inflammatories; Antipsoriatics; Small molecules
- Mechanism of Action CMKLR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 01 Feb 2012 Discontinued - Phase-I for Psoriasis in USA (PO)
- 26 Jan 2011 Phase-I clinical trials in Psoriasis in USA (PO)
- 24 Jul 2007 Preclinical development is ongoing